Mepolizumab
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
- Mepolizumab
- Mepolizumab: From Undocumented Original Indication to Thrombocytopenia Due to Immune Destruction
Mepolizumab: From Undocumented Original Indication to Thrombocytopenia Due to Immune Destruction
One-Sentence Summary
Mepolizumab (DrugBank DB06612) is a monoclonal antibody with no confirmed original indication or marketing record in the current dataset. The TxGNN model predicts it may be effective for thrombocytopenia due to immune destruction, with 0 clinical trials and 1 publication (a case report) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Data not available (no license or indication records in this evidence pack) |
| Predicted New Indication | Thrombocytopenia due to immune destruction |
| TxGNN Prediction Score | 99.66% |
| Evidence Level | L4 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap). Based on the repurposing rationale provided, mepolizumab is known to act as an anti-IL-5 monoclonal antibody, working by suppressing eosinophil proliferation and activation.
The link to this predicted indication comes from a single case report describing resolution of a steroid-resistant, eosinophil-driven immune diathesis (with concomitant thrombotic microangiopathy) after mepolizumab treatment. In that case, suppressing eosinophils appeared to indirectly relieve immune-mediated platelet destruction. However, this is an indirect mechanism — mediated through eosinophil-driven immune dysregulation — rather than a direct effect on anti-platelet antibodies or the megakaryocyte pathway. No mechanistic or clinical data directly connect IL-5 inhibition to platelet destruction pathways.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28648630 | 2018 | Case Report | Blood Cells, Molecules & Diseases | Resolution of a steroid-resistant, eosinophil-driven immune diathesis and concomitant thrombotic microangiopathy following mepolizumab treatment in a patient with atypical HUS-associated hypereosinophilia |
US Market Information
No marketing authorization records are currently available — mepolizumab has 0 registered licenses and is not marketed per this dataset (market status: Not Marketed).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence rests on a single case report (Evidence Level L4) with no supporting clinical trials, and the drug currently has no market presence or regulatory license data in this dataset. A Blocking-severity data gap (TFDA/label warnings and contraindications) also prevents any safety pre-assessment (S1 stage).
To proceed, the following is needed:
- Official label / warning and contraindication data (TFDA or manufacturer labeling)
- Confirmed mechanism of action (MOA) documentation from DrugBank or primary literature
- Confirmed original approved indication(s) for the drug
- Preclinical or mechanistic studies directly linking IL-5/eosinophil inhibition to immune platelet destruction pathways
- Additional independent literature or clinical trial data beyond the single existing case report
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.